“Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment”, J of Skin, vol. 9, no. 6, p. s617, Nov. 2025, doi: 10.25251/gf6mb511.